State of Illinois is investigating pricing of Novo Nordisk's diabetes products
The Danish pharmaceutical company says it has received a civil investigative demand from the Illinois attorney general’s office, meaning Novo Nordisk will have to turn over required documents.
by christian bundgaard, translated by daniel pedersen
On June 23, Novo Nordisk found out that the attorney general of the state of Illinois is looking into the company’s trade practices, in particular relating to its pricing of diabetes products Victoza and Ozempic alongside some insulins, when it received a so-called civil investigative demand, or CID.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US Senators introduce bill to cap insulin prices
For subscribers
